This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Glinsky, G. V. Articles by Metcalf, J. B. Search for Related Content PubMed PubMed Citation Articles by Glinsky, G. V. Articles by Metcalf, J. B.

Inhibition of Human Breast Cancer Metastasis in Nude Mice by Synthetic Glycoamines¹

Cancer Research Center [G. V. G., V. V. G.] and Department of Biochemistry [G. V. G., V. V. G., V. V. M.], University of Missouri, Columbia, Missouri 65201; Metastat, Inc., Portland-Eugene, Oregon, and Columbia, Missouri 65201 [G. V. G., J. B. M.]; Department of Cell Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77054 [J. E. P., G. K.]

We have examined the effect of synthetic low molecular weight glycoamine analogues on the metastasis of MDA-MB-435 human breast carcinoma xenografts growing in the mammary fat pads of nude mice. Initial in vitro screening of a panel of synthetic glycoamines was performed using a clonogenic growth assay in 0.9% agarose. Eight of nine compounds manifested a significant dose-dependent inhibition of colony formation by MDA-MB-435 cells in 0.9% agarose. The relative activity ranks of the compounds, based on ID₅₀s independently determined for each synthetic glycoamine analogue, identified N-(1-deoxy-D-lactulos-1-yl)-L-leucine (Lac-L-Leu), N-(1-deoxy-D-fructos-1-yl)-D-leucine (Fru-D-Leu), N-(1-deoxy-D-fructos-1-yl)-L-phenylalanine, and n-(1-deoxy-D-fructos-1-yl)-L-leucine as the most effective inhibitors of colony formation. Two separate experimental treatment protocols were used to examine the effect of selected synthetic glycoamines on human breast cancer growth and metastasis in athymic nude mice. Group A mice were treated intraperitoneally daily from day 2 after injection of the breast cancer cells until the end of the experiment (17 weeks). In group B, the mice were untreated until the mean tumor diameter was 10 mm, at which time daily i.p. treatment began. After 7 days, the primary tumors were resected, and the mice were treated for an additional 4 weeks (a total of 5 weeks of treatment). The synthetic glycoamines did not have significant antitumor effects, and there was no difference in the tumor incidence or tumor growth rates in mice treated continuously with synthetic glycoamines or PBS. The significant antimetastatic activity of synthetic glycoamines was detected in both experimental treatment protocols. In mice continuously treated with synthetic glycoamines according to protocol A, the incidence of metastasis was decreased 4.6-fold (P = 0.014) and 2.7-fold (P = 0.031) in mice treated with Fru-D-Leu and Lac-L-Leu, respectively. In mice in protocol B, the incidence of pulmonary metastasis was decreased 1.9-fold (P = 0.069) and 2.5-fold (P = 0.042) in mice treated with Fru-D-Leu and Lac-L-Leu, respectively. Correspondingly, the average number of spontaneous pulmonary metastases was reduced from 37 in control mice to 0.2 (P = 0.005) and 0.9 (P < 0.02) in mice treated according to the protocol A with Fru-D-Leu and Lac-L-Leu, respectively. Treatment of mice with N-(1-deoxy-D-fructos-1-yl)-L-leucine did not have significant antimeta-static effects, and no reduction in metastasis incidence or number was noted in mice treated with this synthetic glycoamine analogue. The treated animals had no apparent toxicity from chronic daily injection (up to 17 weeks of treatment) of synthetic glycoamines, and no obvious pathology was noted in the histological slides of the livers, kidneys, or spleens of the treated mice. Therefore, we have identified two synthetic glycoamines (Fru-D-Leu and Lac-L-Leu) that were the effective inhibitors of spontaneous human breast cancer metastasis in nude mice. Potential mechanisms for antimetastatic activity of synthetic glycoamines may include the inhibition of ß-galectin-mediated homotypic cancer cell aggregation and induction of apoptosis in target cells.

¹ This work was supported in part by NIH/National Cancer Institute Grant 1R43 CA61402-01 and Metastat, Inc.

² To whom requests for reprints should be addressed, at Cancer Research Center, 3501 Berrywood Drive, Columbia, MO 65201. Phone: (573) 875-2255; Fax: (573) 443-1202.

Received 8/12/96. Accepted 10/16/96.

This article has been cited by other articles:

				V. V. Mossine, P. Chopra, and T. P. Mawhinney Interaction of Tomato Lycopene and Ketosamine against Rat Prostate Tumorigenesis Cancer Res., June 1, 2008; 68(11): 4384 - 4391. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Toward a Core Nutraceutical Program for Cancer Management Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF]

				G. A. Rabinovich, A. Cumashi, G. A. Bianco, D. Ciavardelli, I. Iurisci, M. D'Egidio, E. Piccolo, N. Tinari, N. Nifantiev, and S. Iacobelli Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis Glycobiology, March 1, 2006; 16(3): 210 - 220. [Abstract] [Full Text] [PDF]

				O. Berezovskaya, A. D. Schimmer, A. B. Glinskii, C. Pinilla, R. M. Hoffman, J. C. Reed, and G. V. Glinsky Increased Expression of Apoptosis Inhibitor Protein XIAP Contributes to Anoikis Resistance of Circulating Human Prostate Cancer Metastasis Precursor Cells Cancer Res., March 15, 2005; 65(6): 2378 - 2386. [Abstract] [Full Text] [PDF]

				J. Zou, V. V. Glinsky, L. A. Landon, L. Matthews, and S. L. Deutscher Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion Carcinogenesis, February 1, 2005; 26(2): 309 - 318. [Abstract] [Full Text] [PDF]

				G. V. Glinsky, T. Higashiyama, and A. B. Glinskii Classification of Human Breast Cancer Using Gene Expression Profiling as a Component of the Survival Predictor Algorithm Clin. Cancer Res., April 1, 2004; 10(7): 2272 - 2283. [Abstract] [Full Text] [PDF]

				A. B. Glinskii, B. A. Smith, P. Jiang, X.-M. Li, M. Yang, R. M. Hoffman, and G. V. Glinsky Viable Circulating Metastatic Cells Produced in Orthotopic but not Ectopic Prostate Cancer Models Cancer Res., July 15, 2003; 63(14): 4239 - 4243. [Abstract] [Full Text] [PDF]

				V. V. Glinsky, G. V. Glinsky, O. V. Glinskii, V. H. Huxley, J. R. Turk, V. V. Mossine, S. L. Deutscher, K. J. Pienta, and T. P. Quinn Intravascular Metastatic Cancer Cell Homotypic Aggregation at the Sites of Primary Attachment to the Endothelium Cancer Res., July 1, 2003; 63(13): 3805 - 3811. [Abstract] [Full Text] [PDF]

				S. K. Khaldoyanidi, V. V. Glinsky, L. Sikora, A. B. Glinskii, V. V. Mossine, T. P. Quinn, G. V. Glinsky, and P. Sriramarao MDA-MB-435 Human Breast Carcinoma Cell Homo- and Heterotypic Adhesion under Flow Conditions Is Mediated in Part by Thomsen-Friedenreich Antigen-Galectin-3 Interactions J. Biol. Chem., January 31, 2003; 278(6): 4127 - 4134. [Abstract] [Full Text] [PDF]

				P. Nangia-Makker, V. Hogan, Y. Honjo, S. Baccarini, L. Tait, R. Bresalier, and A. Raz Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin J Natl Cancer Inst, December 18, 2002; 94(24): 1854 - 1862. [Abstract] [Full Text] [PDF]

				S. K. Green, M. C. I. Karlsson, J. V. Ravetch, and R. S. Kerbel Disruption of Cell-Cell Adhesion Enhances Antibody-dependent Cellular Cytotoxicity: Implications for Antibody-based Therapeutics of Cancer Cancer Res., December 1, 2002; 62(23): 6891 - 6900. [Abstract] [Full Text] [PDF]

				V. V. Glinsky, G. V. Glinsky, K. Rittenhouse-Olson, M. E. Huflejt, O. V. Glinskii, S. L. Deutscher, and T. P. Quinn The Role of Thomsen-Friedenreich Antigen in Adhesion of Human Breast and Prostate Cancer Cells to the Endothelium Cancer Res., June 1, 2001; 61(12): 4851 - 4857. [Abstract] [Full Text] [PDF]

				V. V. Glinsky, M. E. Huflejt, G. V. Glinsky, S. L. Deutscher, and T. P. Quinn Effects of Thomsen-Friedenreich Antigen-specific Peptide P-30 on {beta}-Galactoside-mediated Homotypic Aggregation and Adhesion to the Endothelium of MDA-MB-435 Human Breast Carcinoma Cells Cancer Res., May 1, 2000; 60(10): 2584 - 2588. [Abstract] [Full Text]